ArticleBMC infectious diseases2025
Seroepidemiology of Toxoplasma gondii infection among patients with beta-thalassemia major: a case-control study in Southeastern Iran.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Serological, Molecular, and Epidemiological Investigation ofTropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundToxoplasmosis could potentially be transmitted via blood transfusions from asymptomatic donors to patients with beta-thalassemia major (BTM) who regularly receive transfusions. Nevertheless, screening for toxoplasmosis prior to blood donation has not been implemented, representing a significant gap in transfusion safety protocols. This study aimed to investigate the seroprevalence of anti-Toxoplasma gondii antibodies in BTM patients undergoing blood transfusion.
methodsThe current case-control study was conducted among 270 patients and 90 controls in Southeastern Iran, from September to December 2024. The enzyme-linked immunosorbent assay was utilized to detect anti-T. gondii IgG and IgM antibodies in serum samples. A binomial logistic regression model was employed to analyze the association between toxoplasmosis and its determinants.
resultsThe seropositivity rate for anti-T. gondii IgG antibodies was 9.3% (25/270) in the patients and 8.9% (8/90) in the controls. The difference between the two groups was not statistically significant (OR = 1.05; 95% CI: 0.45–2.41; p = 0.916). Anti-T. gondii IgM antibodies were detected in the patients with a seropositivity rate of 1.5% (4/270). In the controls, the seropositivity rate for anti-T. gondii IgM antibodies was 0.0% (0/90). None of the participants’ characteristics were found to be associated with the infection.
conclusionAnti-T. gondii antibodies were detected at relatively low seroprevalence rates in both patients and controls. The presence of toxoplasmosis in these patients highlights the critical need for appropriate strategies to reduce the risk of infection, as the population appears to be mostly non-immune. It is essential to implement routine screening of blood for specific antibodies against T. gondii before transfusions in these patients to mitigate the risk of infection. This is the first study assessing the seroprevalence of T. gondii antibodies among patients with BTM in Southeastern Iran.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.